ASKA Pharmaceutical Holdings Co.,Ltd.
Supplementary Materials to Financial Summary for the Second Quarter of the Fiscal Year Ending March 2027
Revenue of 35,600 million yen (YoY +1.1%), operating income of 2,700 million yen (YoY +3.5%), and a decrease in interim net income attributable to owners of parent by 213 million yen. Domestic prescription pharmaceuticals and animal health businesses remained solid, while overseas operations saw declines in revenue and profit. Increased R&D expenses offset in part by reductions in certain SG&A items led to higher profit. Consolidated results for the second quarter of the fiscal year ending March 2027 were released.
Key Figures
- Revenue: 35,600 million yen (YoY +1.1%)
- Operating Income: 2,700 million yen (YoY +3.5%)
- Ordinary Income: 2,862 million yen (YoY +8.5%)
AI要約
Overview of Performance
Highlights show revenue of 35,600 million yen (YoY +1.1%), operating income of 2,700 million yen (YoY +3.5%), ordinary income up 8.5% YoY, and a decrease in interim net income attributable to owners of parent compared with the same period last year. The overall performance was supported by steady trends in domestic prescription pharmaceuticals and the animal health business. Meanwhile, overseas operations experienced declines in both revenue and profit, and increased research and development expenses partially offset by some reductions in selling, general and administrative expenses were contributing factors.
Outlook and Main Factors
The full-year plan sets revenue at 73,000 million yen and operating income at 6,200 million yen. The supplementary materials to the financial summary indicate there are no changes to guidance going forward; despite increased R&D expenses, SG&A improved due to cost reductions such as transportation and storage expenses.
Revenue Trend
Operating Income Trend
Interim Net Income Attributable to Owners of Parent Trend
Segment Revenue Breakdown
Margin Analysis
ASKA Pharmaceutical Holdings Co.,Ltd.
Company overview · Stock price · Financial data · All IR
